Patents by Inventor Luis A. Diaz

Luis A. Diaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160060275
    Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: April 21, 2014
    Publication date: March 3, 2016
    Inventors: José-Luís DÍAZ-FERNÁNDEZ, Carmen ALMANSA-ROSALES, Félix CUEVAS-CORDOBÉS
  • Publication number: 20150352098
    Abstract: The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: August 20, 2015
    Publication date: December 10, 2015
    Inventors: José-Luis DIAZ-FERNÁNDEZ, Ute CHRISTMANN
  • Publication number: 20150353510
    Abstract: The present invention relates to new 1,2,3-triazole-amine derivatives, having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments for the treatment of sigma receptor related diseases and disorders.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 10, 2015
    Inventors: Antoni TORRENS-JOVER, Ute CHRISTMANN, Josè-Luis DIAZ-FERNÁNDEZ, Carmen ALMANSA-ROSALES
  • Publication number: 20150344970
    Abstract: Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.
    Type: Application
    Filed: July 2, 2015
    Publication date: December 3, 2015
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Victor Velculescu, Luis Diaz, Rebecca J. Leary
  • Patent number: 9193738
    Abstract: The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: November 24, 2015
    Assignee: LABORATORIOS DEL DR. ESTEVE S.A.
    Inventors: José-Luis Diaz-Fernández, Ute Christmann
  • Patent number: 9181195
    Abstract: The invention refers to compounds of general formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: November 10, 2015
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Mónica García López, Antoni Torrens Jover, José Luis Díaz Fernández, Ana María Caamaño Moure
  • Publication number: 20150315190
    Abstract: New pyrazolo[3,4-d]pyrimidine compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for preparing these compounds, to compositions comprising them and to their use as medicaments.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 5, 2015
    Inventors: Maria Rosa CUBERES-ALTISENT, Jordi CORBERA-ARJONA, Jose Luis DIAZ-FERNANDEZ, Carmen ALMANSA-ROSALES
  • Publication number: 20150315192
    Abstract: The present invention relates to new substituted pyrazolo[3,4-d]pyrimidine compounds, having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: November 14, 2013
    Publication date: November 5, 2015
    Inventors: José Luis DÍAZ FERNÁNDEZ, Carme ALMANSA, Jordi CORBERA ARJONA
  • Publication number: 20150292027
    Abstract: The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.
    Type: Application
    Filed: October 17, 2013
    Publication date: October 15, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Isaac Kinde, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis Diaz, Chetan Bettegowda, Yuxuan Wang
  • Publication number: 20150252415
    Abstract: Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children. We performed whole-genome sequencing (6 cases), exome sequencing (16 cases), genome-wide rearrangement analyses (32 cases), and targeted analyses of specific genomic loci (40 cases) using massively parallel sequencing to determine the genetic basis for neuroblastoma. On average, each tumor had 19 somatic alterations in coding genes (range, 3-70). Chromosomal deletions and sequence alterations of chromatin remodeling genes, ARID1A and ARID1B, were identified in 8 of 71 neuroblastomas (11%), and these were associated with early treatment failure and decreased survival. These results highlight dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of neuroblastoma patients.
    Type: Application
    Filed: October 14, 2013
    Publication date: September 10, 2015
    Applicants: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Victor Velculescu, Luis Diaz, Nickolas Papadopoulos, Mark Sausen, Rebecca Leary, John Maris, Michael Hogarty
  • Publication number: 20150164602
    Abstract: An apparatus for cleaning an instrument with a cleaning fluid includes a vessel defining a chamber and a port for at least partially filling the chamber with the fluid. The apparatus further includes an ultrasonic transducer for delivering ultrasonic energy to the fluid, and a vacuum pump for depressurizing the chamber. The apparatus further includes a rotatable device removably disposable in the chamber and having a rack defining a cavity for supporting the instrument. The rotatable device also has a fluid delivery member extending toward the cavity and having a fluid channel between an inlet and an outlet. The apparatus further includes a fluid transmission system in fluid communication with the chamber and the fluid channel of the fluid delivery member for circulating the fluid from the chamber through the fluid channel of the fluid delivery member. A method of cleaning an instrument is also provided.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 18, 2015
    Applicant: Stryker Sustainability Solutions, Inc.
    Inventors: Jose Vasquez, Luis Diaz, Dan Peterson, Ed Cantey, Jody Berkey, Dan Fowler, Brian Thomas, Miguel J. Gonzalez
  • Publication number: 20150166574
    Abstract: The present invention relates to new imidazo[2,1-b]thiazole derivatives having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: July 4, 2013
    Publication date: June 18, 2015
    Inventors: María de las Ermitas Alcalde-Pais, José-Luís Díaz-Fernández, María de les Neus Mesquida-Estevez, Laura Paloma-Romeu
  • Publication number: 20150158831
    Abstract: The present invention relates to new indene derivatives having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: July 3, 2013
    Publication date: June 11, 2015
    Inventors: María de las Ermitas Alcalde-Pais, Carmen Almansa-Rosales, José Luís Diaz Fernández, María de les Neus Mesquida-Estevez, Laura Paloma-Romeu
  • Publication number: 20150031678
    Abstract: The present invention relates to new substituted pyrazolo[1,5-a]pyridine having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 29, 2015
    Applicant: LABORATORIES DEL DR. ESTEVE S.A.
    Inventors: José Luis Diaz Fernández, Ma Rosa Cuberes Altisent
  • Publication number: 20150031692
    Abstract: The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: January 24, 2013
    Publication date: January 29, 2015
    Inventors: José-Luis Diaz-Fernández, Ute Christmann
  • Publication number: 20140227271
    Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.
    Type: Application
    Filed: June 28, 2012
    Publication date: August 14, 2014
    Applicants: DUKE UNIVERSITY, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
  • Publication number: 20140179538
    Abstract: To help reveal the pathogenesis of these lesions, we purified the DNA from Intraductal Papillary Mucinous Neoplasm (IPMN) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of GNAS. We found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. These data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.
    Type: Application
    Filed: June 22, 2012
    Publication date: June 26, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Jian Wu, Luis Diaz, Nickolas Papadopoulos, Hanno Matthaei, Ralph Hruban, Anirban Maitra
  • Publication number: 20140163010
    Abstract: New pyrazolo[3,4-d]pyrimidine compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for preparing these compounds, to compositions comprising them and to their use as medicaments.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 12, 2014
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Maria Rosa Cuberes-Altisent, Jordi Corbera-Arjona, Jose Luis Diaz-Fernanadez, Carmen Almansa-Rosales
  • Patent number: 8709040
    Abstract: A suture anchor includes two clamping surfaces that secure one or more suture strands between them. Cooperating engaging structures, such as recesses and a projection enable the clamping surfaces to be incrementally moved closer together such that the force applied between the clamping surfaces is increased in predetermined increments to secure the suture strands. If the applied force is too high, the clamping surfaces can be released from a fixed position, and the force applied by the clamping surfaces can again be incrementally increased to the desired clamping force. A guide is provided to mark the location of the hole that has been drilled in the bone. A suture anchor delivery tool is provided to insert and secure the suture anchor in the hole in the bone. The suture anchor delivery tool enables the surgeon to move the clamping surfaces of the suture anchor towards each other.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: April 29, 2014
    Assignee: VitaSynergies, LLC
    Inventors: Otto E. Anderhub, Sigfrido Delgado, Luis A. Diaz
  • Publication number: 20140045881
    Abstract: Pancreatic Neuroendocrine Tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of PanNETs, we determined the exomic sequences of ten non-familial PanNETs and then screened the most commonly mutated genes in 58 additional PanNETs. Remarkably, the most frequently mutated genes specify proteins implicated in chromatin remodeling: 44% of the tumors had somatic inactivating mutations in MEN-1, which encodes menin, a component of a histone methyltransferase complex; and 43% had mutations in genes encoding either of the two subunits of a transcription/chromatin remodeling complex consisting of DAXX (death-domain associated protein) and ATRX (alpha thalassemia/mental retardation syndrome X-linked). Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 13, 2014
    Applicant: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Victor Velculescu, Luis Diaz, Nikolas Papadopoulos, Yuchen Jiao, Ralph Hruban